Lisa Judith Kolenchery

Ms. Lisa Judith Kolenchery

JKU Faculty of Medicine, Linz, Oberösterreich, Austria
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
MHMatthias Wolfgang Heinzl
Matthias Wolfgang Heinzl
LKLisa Judith Kolenchery
Lisa Judith Kolenchery
MRMichael Resl
Michael Resl
CKCarmen Klammer
Carmen Klammer
ABAnne Black
Anne Black
MCMartin Clodi
Martin Clodi
Background: Although vaccination against COVID-19 is highly effective, breakthrough infections occur, often leading to severe courses and death. The extent of protection provided by individual antibody levels in breakthrough infections is still unknown and cut-off levels have yet to be determined. Methods: In 80 consecutive fully vaccinated patients hospitalized between August and December 2021 with COVID-19 breakthrough infection (Delta variant), anti-CoV2S antibody levels were analyzed for the endpoint of death. Results: Ten out of the 12 patients who died (83.3%) had antibody levels < 600 U/mL; 5 (41.7%) of these had antibody levels < 200 U/mL. Only 2 patients with a level of >600 U/mL died from vaccine breakthrough infection. Correction for the number of comorbidities and age revealed that anti-CoV2S antibody levels at the time of hospitalization were a significant predictor for reduced risk of death (OR = 0.402 for every 1000 U/mL, p = 0.018). Conclusions: In this retrospective data analysis, we show that almost all patients who died from COVID-19 vaccine breakthrough infection had antibody levels < 600 U/mL, most of them below 200 U/mL. In logistic regression corrected for the number of comorbidities and age, anti-CoV2S antibody levels at the time of hospitalization proved to be a significantly protective predictor against death.

28 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MHMatthias Wolfgang Heinzl
Matthias Wolfgang Heinzl
MFMarkus Freudenthaler
Markus Freudenthaler
PFPaul Fellinger
Paul Fellinger
LKLisa Judith Kolenchery
Lisa Judith Kolenchery
MRMichael Resl
Michael Resl
MCMartin Clodi
Martin Clodi
Background: Although it is known that high-density lipoprotein (HDL) exerts important anti-inflammatory effects and that low HDL plasma concentrations represent a negative prognostic marker in bacterial infections and sepsis, not much is known about possible implications of HDL in acute viral infections such as influenza. Methods: We performed a retrospective, single-centre analysis of influenza patients hospitalised during the 2018/19 and 2019/20 influenza seasons and analysed the impact of HDL concentrations on inflammation and mortality. Results: 199 influenza patients (173 male patients) were admitted during the 2018/19 and 2019/20 influenza seasons with a mortality rate of 4.5%. HDL was significantly lower in deceased patients (median HDL 21 (IQR 19–25) vs. 35 (IQR 28–44) mg/dL; p = 0.005). Low HDL correlated with increased inflammation and HDL was an independent negative predictor regarding mortality after correction for age and the number of comorbidities both overall (OR = 0.890; p = 0.008) and in male patients only (OR = 0.891; p = 0.009). Conclusions: Low HDL upon hospital admission is associated with increased inflammation and is an independent predictor for increased mortality in male patients with influenza A.